PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial Results
31 oct. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable
27 oct. 2022 08h00 HE
|
PDS Biotechnology Corporation
Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA®, presents interim data from the study Combination shows potential to achieve oncologists’ goals...
PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference
25 oct. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...